Fintel reports that on September 8, 2026, WestPark Capital initiated coverage of Akebia Therapeutics (NASDAQCM:AKBA) with a Buy recommendation.
Akebia Therapeutics, Inc. is a United States-based biopharmaceutical company that focuses on developing and commercializing therapeutics for patients with kidney disease. The company is involved in the development of treatments addressing complications related to kidney disease, including its key product, Auryxia® (ferric citrate). This product is approved for controlling serum phosphorus levels in chronic kidney disease patients on dialysis and for treating iron deficiency anemia in adult patients with chronic kidney disease not on dialysis.
Prior to this coverage initiation, the company’s stock closed at $0.97 on September 4, 2026. This latest close represents a one-week price change of +10.94% from the baseline close of $0.88 on August 28, 2026. Over a one-month period, the stock experienced a price change of -26.16% from the baseline close of $1.32 on August 4, 2026.
Akebia Therapeutics last reported earnings on August 5, 2026, posting an actual EPS of -0.03 compared to the estimated EPS of -0.0449. The company’s actual revenue was $49,128,000,000,000.00, compared to the estimated revenue of $49,838,424,000,000.00.
Separately from WestPark Capital’s individual rating, the broader analyst consensus target mean for the stock was $3.88 as of August 28, 2026, with a median target of $4.08. This mean target represents an implied change of +297.66% from prior levels. The prior consensus target mean was $4.28 as of August 4, 2026, reflecting a consensus target revision of -9.52%.
In terms of overall recommendations, as of the September 1, 2026 period, the consensus consisted of 4 strong buy, 5 buy, 2 hold, 0 sell, and 0 strong sell recommendations, totaling 11. This represents 81.8% positive recommendations and 18.2% hold recommendations. In the prior period of August 1, 2026, the total of 11 recommendations included 5 strong buy, 5 buy, 1 hold, 0 sell, and 0 strong sell ratings, representing 90.9% positive and 9.1% hold recommendations.
Recent analyst actions
Recent analyst upgrades, downgrades, initiations, and maintained ratings Date Analyst Prior Latest recommendation Action September 8, 2026 WestPark Capital Buy initiated coverage
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
Click to Learn More
This story originally appeared on Fintel.
